Starling Oncology, Inc. (STLN) · Sep 1, 2026 · Exec change
Director departure — Hively will not stand for re-election at the 2027 annual meeting
Brad Hively will not seek reelection and immediately leaves Starling Oncology’s vice-chair and committee roles, without citing company disagreement.
This is a governance transition, not an operating update. Brad Hively plans to leave Starling Oncology’s board after the 2027 annual meeting and has already stepped down as vice chairman and from all board committees.
The immediate change is broader than a future director retirement. Hively is expected to remain a director until the annual meeting, but no longer holds the vice-chair role or committee assignments. 〔0〕
Relative to expectations, there is no clean beat-or-miss benchmark. The filing gives no indication of an operational, financial, or strategic impact, and explicitly says the decision was not caused by a disagreement with the company. 〔1〕
Net read: a new but currently neutral board-change disclosure. The material item to monitor is who replaces Hively as vice chairman and on the committees, particularly Compliance, before the 2027 annual meeting.
2027 annual meeting and board succession
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!